Mission Statement
Our mission is to develop innovative technology with steering capability that will enable greater precision while targeting difficult to reach lung nodules.
Clinical Differentiation
Endobronchial tools that offer articulation at the distal tip to enable physicians to reach difficult targets with predictable tool positioning and enhanced precision, including those outside the airway.
Facts about Lung Cancer
#1
Lung cancer (both small cell and non-small cell) is the second most common cancer ... and by far the leading cause of cancer death , making up almost 25% of all cancer deaths. 1
20%
National Lung Screening Trial found that annual screening with Low-Dose Computed Tomography (LDCT) was associated with a 20% reduction in mortality in high risk patients.2
1.6M
Pulmonary nodules are identified in approximately 1.6 million patients per year in the US3
Lung Cancer Screening Criteria4,5
U.S. Preventive Services Task Force advises that health care providers, and people at increased risk for lung cancer, follow the recently updated recommendations for annual lung cancer screening
These organizations recommend yearly lung cancer screening with LDCT scans for people who:
- Are 50 to 80 years old and in fairly good health, and...
- Currently smoke or have quit in the past 15 years, and...
- Have at least a 20 pack-year smoking history.
In addition, it’s important that people who are going to be screened:
- Receive counseling to quit smoking if they currently smoke,
- Have been told by their doctor about the possible benefits, limits, and harms of screening with LDCT scans,
- Can go to a center that has experience in lung cancer screening and treatment.
Executive Team
Sasha Schrode
President & CEO
Duke Rohlen
Executive Chairman
Joe Koblish
CTO
Aftab Kherani, MD
Executive Vice Chairman
Doug Koo
CFO
Jocelyn Jackson
VP of Finance
Cason Kynes
VP of Business Development
Sarah St. Laurent
Human Resources Manager
Eliza Lawrence
VP of Clinical
Development Team
Ken Berliner
R&D Manager, Principal Engineer
Eza Koch
Principal Engineer
Chau Cao
Senior Technician
Riley Ennis
R&D Engineer
Maritza Fuerte
R&D Engineer
Clinical Advisory Team
Jeremy Durack, MD
Chief Clinical Officer, Ajax Health and Cordis Accelerator
Andrew Haas, MD, PhD
Director, Interventional
Pulmonology and
Thoracic Oncology,
Hospital of the University
of PennsylvaniaMichael Machuzak, MD
Interventional Pulmonologist & Associate in Pulmonary, Allergy & Critical Care. The Cleveland Clinic Cancer Center.
Momen Wahidi, MD
Interventional Pulmonologist, Professor of Medicine, Duke University Hospital, Duke Cancer Center
Mohit Chawla, MD
Interventional Pulmonologist & Chief of Pulmonary, Memorial Slone Kettering
Eric Seeley, MD
Director, Bronchoscopy and Interventional Pulmonary Medicine,
UC San Francisco
George Cheng, MD, PhD
Medical Director, Interventional Pulmonary, Bronchoscopy & Pleural Services and Associate Professor of Medicine,
UC San Diego
Kyle Hogarth, MD
Director of Bronchoscopy, Professor of Medicine, Medical Director, University of Chicago. Founder of the Society for Advanced Bronchoscopy
Alexander Chen, MD
Interventional Pulmonogist, Instructor of Medicine, Washington University in St. Louis, Siteman Cancer Center
CONTACT US
Please reach out to learn more.
References
- American Cancer Society. Key Statistics for Lung Cancer https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html
- The National Lung Screening Trial Research Team. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med 2011; 365:395-409. DOI: 10.1056/NEJMoa1102873
- Mazzone PJ, Lam L. Evaluating the Patient With a Pulmonary Nodule: A Review. JAMA. 2022 Jan 18;327(3):264-273. doi: 10.1001/jama.2021.24287. PMID: 35040882.
- Final Recommendation Statement: Lung Cancer Screenings. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening
